GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » Institutional Ownership

Bio-Techne (FRA:TE1) Institutional Ownership : 79.34% (As of Jan. 19, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bio-Techne's institutional ownership is 79.34%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bio-Techne's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bio-Techne's Float Percentage Of Total Shares Outstanding is 87.21%.


Bio-Techne Institutional Ownership Historical Data

The historical data trend for Bio-Techne's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Institutional Ownership Chart

Bio-Techne Historical Data

The historical data trend for Bio-Techne can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31
Institutional Ownership 78.69 78.19 79.08 79.47 80.20 79.94 79.21 79.09 79.27 79.34

Bio-Techne Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Bio-Techne Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Headlines

No Headlines